Celldex Therapeutics (NASDAQ:CLDX) Trading 3.2% Higher

Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s share price was up 3.2% during trading on Wednesday . The company traded as high as $42.59 and last traded at $42.56. Approximately 11,587 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 767,168 shares. The stock had previously closed at $41.24.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a research note on Monday, August 12th. Wells Fargo & Company increased their target price on shares of Celldex Therapeutics from $35.00 to $37.00 and gave the stock an “equal weight” rating in a research note on Monday, August 12th. Wolfe Research started coverage on Celldex Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating and a $51.00 price target on the stock. Stifel Nicolaus assumed coverage on Celldex Therapeutics in a research note on Tuesday, June 18th. They set a “buy” rating and a $58.00 price objective for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research note on Monday. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Celldex Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $63.83.

Celldex Therapeutics Stock Up 4.6 %

The stock has a market capitalization of $2.86 billion, a PE ratio of -14.47 and a beta of 1.56. The firm’s fifty day moving average is $38.35 and its 200-day moving average is $38.76.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. The business had revenue of $2.50 million during the quarter, compared to the consensus estimate of $1.13 million. On average, analysts expect that Celldex Therapeutics, Inc. will post -2.5 EPS for the current year.

Hedge Funds Weigh In On Celldex Therapeutics

A number of large investors have recently made changes to their positions in the stock. Victory Capital Management Inc. purchased a new stake in Celldex Therapeutics during the fourth quarter worth about $288,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Celldex Therapeutics by 13.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 409,391 shares of the biopharmaceutical company’s stock worth $16,236,000 after acquiring an additional 47,844 shares in the last quarter. UBS Group AG boosted its stake in shares of Celldex Therapeutics by 645.9% during the 4th quarter. UBS Group AG now owns 158,092 shares of the biopharmaceutical company’s stock worth $6,270,000 after acquiring an additional 136,897 shares in the last quarter. Trexquant Investment LP acquired a new stake in shares of Celldex Therapeutics in the 4th quarter worth approximately $1,246,000. Finally, Aigen Investment Management LP purchased a new position in Celldex Therapeutics in the 4th quarter valued at approximately $251,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.